Alexa

30 Ethical Companies of the Year 2019

INSYS Therapeutics, Inc., a Commercial-stage Specialty Pharmaceutical Company, Develops and Commercializes Supportive Care Products

thesiliconreview-saeed-motahari-ceo-insys-therapeutics-inc-19

“SUBSYS® is used for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.”

 Life sciences companies face unprecedented challenges as revenues come under pressure as a consequence of pricing pressures caused by healthcare reforms and austerity measures, increased competition, and challenges in bringing new drugs and other products to market.

They are responding by focusing on growth opportunities in emerging markets, pursuing breakthrough innovation through collaboration with industry and academic partners.

In view of the above-mentioned scenario, we’re delighted to present INSYSTherapeutics, Inc.

INSYS,a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia.

In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for the opioid antagonist.

INSYS was incorporated in 1990 and is headquartered in Chandler, Arizona.

INSYS: Synopsis

Innovative Pharmaceutical Products

INSYSseeks to improve the quality of patient care by building a specialty pharmaceutical company focused on cannabinoids and novel drug delivery systems that address unmet patient needs.

SUBSYS® is used for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.

The product is the first and only breakthrough pain medication for patients with cancer offered as a sublingual spray. It may provide pain relief in as little as 5 minutes. SUBSYS® is a unique fentanyl sublingual spray that delivers a fine mist of medication underneath the tongue to provide pain relief. It is the first and only sublingual spray for breakthrough cancer pain approved by the FDA.

SYNDROS® is a cannabinoid medicine used in adults to treat:

Loss of appetite (anorexia) in people with AIDS (Acquired Immune Deficiency Syndrome) who have lost weight

Nausea and vomiting caused by anti-cancer medicine (chemotherapy) in people whose nausea and vomiting have not improved with usual anti-nausea and vomiting medicines

The product is the first and only FDA-approved liquid dronabinol, which allows for fast absorption, flexible dosing and a potential solution for patients who may prefer a liquid medication.

Products in Development

INSYS is focused on developing and commercializing innovative drugs and novel drug delivery systems that improve the quality of patients’ lives.

Through itsproprietary spray technology and its capability to develop pharmaceutical cannabinoids, INSYShas improved the properties of existing molecules. What does this mean for patients? With each product, the company makes available better solutions that can provide relief around the conditions that burden their lives.

INSYS’s product pipeline is aimed at addressing conditions with unmet medical needs, such as refractory pediatric epilepsy (including childhood absence epilepsy and infantile spasms), the genetic disorder Prader-Willi syndrome, anorexia-associated weight loss in cancer patients, agitation in Alzheimer's disease, migraine, anaphylaxis (severe allergic reaction), acute pain, opioid dependence and reversal of opioid-induced respiratory depression.

Following are the products that are under development: Cannabidiol oral solution, Dronabinol inhalation, Buprenorphine sublingual spray, Buprenorphine/Naloxone sublingual spray, Epinephrine nasal spray, and Naloxone nasal spray

Saeed Motahari, President/CEO: A Brief Background

Saeed Motahari joined INSYS Therapeutics as President and Chief Executive Officer in April 2017. Prior to joining INSYS, Mr. Motahari served as Chief Commercial Officer at Purdue Pharma L.P., where he led a successful transformation of the commercial organization and contributed to the business development strategy, since May 2014.

Prior to Purdue, Mr. Motahari worked at Abbott Laboratories and AbbVie, serving as Vice President of U.S. Specialty Brands – New Launches, from 2004–2014. He also held P&L responsibility for Specialty Franchises in the Renal, Oncology, Endocrinology, Acute Care, Virology and Neuroscience therapeutic areas. In addition, Mr. Motahari led various commercial organizations at Abbott Laboratories, Bristol-Myers Squibb and Hoffmann-La Roche in managed care, commercial operations, global analytics and new product development.

Mr. Motahari received a BS in Biology and holds a Master’s of Business degree from Concordia University, Montreal, Canada.

“INSYS seeks to improve the quality of patient care by building a specialty pharmaceutical company focused on cannabinoids and novel drug delivery systems that address unmet patient needs.”